相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Aurora A Kinase Inhibition Destabilizes PAX3-FOXO1 and MYCN and Synergizes with Navitoclax to Induce Rhabdomyosarcoma Cell Death
Johannes Ommer et al.
CANCER RESEARCH (2020)
BH3 mimetics selectively eliminate chemotherapy-induced senescent cells and improve response inTP53wild-type breast cancer
Ashkan Shahbandi et al.
CELL DEATH AND DIFFERENTIATION (2020)
Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial
Andrew M. Brunner et al.
LANCET HAEMATOLOGY (2020)
First-in-human study of palcitoclax (APG-1252), a novel dual Bcl-2/Bcl-xL inhibitor, demonstrated advantages in platelet safety while maintaining anticancer effect in U.S. patients with metastatic solid tumors.
Nehal J. Lakhani et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Consensus guidelines for the definition, detection and interpretation of immunogenic cell death
Lorenzo Galluzzi et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Therapy-Induced Senescence: An Old Friend Becomes the Enemy
Tareq Saleh et al.
CANCERS (2020)
The quest to slow ageing through drug discovery
Linda Partridge et al.
NATURE REVIEWS DRUG DISCOVERY (2020)
Preclinical antitumor efficacy of senescence -inducing chemotherapy combined with a nanoSenolytic
Irene Galiana et al.
JOURNAL OF CONTROLLED RELEASE (2020)
Inhibition of Aurora-A Promotes CD8(+) T-Cell Infiltration by Mediating IL10 Production in Cancer Cells
Jing Han et al.
MOLECULAR CANCER RESEARCH (2020)
Cellular Senescence-Inducing Smal Molecules for Cancer Treatment
Peng Liu et al.
CURRENT CANCER DRUG TARGETS (2019)
Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancer
Laura W. Goff et al.
INVESTIGATIONAL NEW DRUGS (2019)
Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial
Andrew D. Zelenetz et al.
BLOOD (2019)
Randomized Phase III Study of Alisertib or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
Owen A. O'Connor et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Phase I trial of alisertib with concurrent fractionated stereotactic re-irradiation for recurrent high grade gliomas
Andrew Song et al.
RADIOTHERAPY AND ONCOLOGY (2019)
The anaphase-promoting complex/cyclosome: a new promising target in diffuse large B-cell lymphoma and mantle cell lymphoma
Anke Maes et al.
BRITISH JOURNAL OF CANCER (2019)
Regulating the BCL2 Family to Improve Sensitivity to Microtubule Targeting Agents
Robert H. Whitaker et al.
CELLS (2019)
Targeting PI3K and PLK1 to Overcome Ibrutinib-Venetoclax Resistance in Mantle Cell Lymphoma
Changying Jiang et al.
BLOOD (2019)
Polo-like kinase 1 (Plk1) inhibition synergizes with taxanes in triple negative breast cancer
Antonio Giordano et al.
PLOS ONE (2019)
Targeting mitosis exit: A brake for cancer cell proliferation
Xinran Liu et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2019)
A phase I trial investigating the Aurora B kinase inhibitor BI 811283 in combination with cytarabine in patients with acute myeloid leukaemia
Hartmut Doehner et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Mitosis inhibitors in anticancer therapy: When blocking the exit becomes a solution
Ana C. Henriques et al.
CANCER LETTERS (2019)
Mitotic slippage: an old tale with a new twist
Debottam Sinha et al.
CELL CYCLE (2019)
Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer A Randomized Clinical Trial
Gerald Falchook et al.
JAMA ONCOLOGY (2019)
Aurora A Protein Kinase: To the Centrosome and Beyond
Laura Magnaghi-Jaulin et al.
BIOMOLECULES (2019)
A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers
Himisha Beltran et al.
CLINICAL CANCER RESEARCH (2019)
Effect of alisertib, an investigational aurora a kinase inhibitor on the QTc interval in patients with advanced malignancies
Xiaofei Zhou et al.
INVESTIGATIONAL NEW DRUGS (2018)
Selective BCL-XL inhibition promotes apoptosis in combination with MLN8237 in medulloblastoma and pediatric glioblastoma cells
Jane Levesley et al.
NEURO-ONCOLOGY (2018)
Identification of JNK1 as a predicting biomarker for ABT-199 and paclitaxel combination treatment
Ting Song et al.
BIOCHEMICAL PHARMACOLOGY (2018)
Vinca alkaloids and analogues as anti-cancer agents: Looking back, peering ahead
Emanuela Martino et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2018)
New tools for old drugs: Functional genetic screens to optimize current chemotherapy
Nora M. Gerhards et al.
DRUG RESISTANCE UPDATES (2018)
Alisertib: a review of pharmacokinetics, efficacy and toxicity in patients with hematologic malignancies and solid tumors
Susanne Liewer et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2018)
A phase 1, first-in-human study of AMG 900, an orally administered pan-Aurora kinase inhibitor, in adult patients with advanced solid tumors
Michael Carducci et al.
INVESTIGATIONAL NEW DRUGS (2018)
Reducing protein regulator of cytokinesis 1 as a prospective therapy for hepatocellular carcinoma
Xinran Liu et al.
CELL DEATH & DISEASE (2018)
Inhibition of kinesin family member 20B sensitizes hepatocellular carcinoma cell to microtubule-targeting agents by blocking cytokinesis
Xinran Liu et al.
CANCER SCIENCE (2018)
Leader of the SAC: molecular mechanisms of Mps1/TTK regulation in mitosis
Spyridon T. Pachis et al.
OPEN BIOLOGY (2018)
PLK1 stabilizes a MYC-dependent kinase network in aggressive B cell lymphomas
Yuan Ren et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Drug-induced aneuploidy and polyploidy is a mechanism of disease relapse in MYC/BCL2-addicted diffuse large B-cell lymphoma
Shariful Islam et al.
Oncotarget (2018)
Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma
Kevin R. Kelly et al.
CLINICAL CANCER RESEARCH (2018)
Microtubule destabilising agents: far more than just antimitotic anticancer drugs
Darcy Bates et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2017)
A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia
B. Vormoor et al.
PEDIATRIC BLOOD & CANCER (2017)
A phase 2 study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group study 0231D
David M. Hyman et al.
GYNECOLOGIC ONCOLOGY (2017)
Disruption of Aneuploidy and Senescence Induced by Aurora Inhibition Promotes Intrinsic Apoptosis in Double Hit or Double Expressor Diffuse Large B-cell Lymphomas
Shariful Islam et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Low-dose paclitaxel suppresses the induction of M2 macrophages in gastric cancer
Takahisa Yamaguchi et al.
ONCOLOGY REPORTS (2017)
Anti-mitotic agents: Are they emerging molecules for cancer treatment?
Larissa Siqueira Penna et al.
PHARMACOLOGY & THERAPEUTICS (2017)
Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer
Delphine Merino et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
High Eg5 expression predicts poor prognosis in breast cancer
Qin Jin et al.
ONCOTARGET (2017)
Chromosomal instability and acquired drug resistance in multiple myeloma
Wang Wang et al.
ONCOTARGET (2017)
Is inflammatory micronucleation the key to a successful anti-mitotic cancer drug?
T. J. Mitchison et al.
OPEN BIOLOGY (2017)
Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics
Abhishek D. Garg et al.
ONCOIMMUNOLOGY (2017)
Aurora A Functional Single Nucleotide Polymorphism (SNP) Correlates With Clinical Outcome in Patients With Advanced Solid Tumors Treated With Alisertib, an Investigational Aurora A Kinase Inhibitor
Huifeng Niu et al.
EBIOMEDICINE (2017)
The Dual Role of Cellular Senescence in Developing Tumors and Their Response to Cancer Therapy
Markus Schosserer et al.
FRONTIERS IN ONCOLOGY (2017)
Mechanisms of resistance of chemotherapy in early-stage triple negative breast cancer (TNBC)
Lironne Wein et al.
BREAST (2017)
A phase 1 study of AMG 900, an orally administered pan-aurora kinase inhibitor, in adult patients with acute myeloid leukemia
Hagop M. Kantarjian et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
A phase I study of MK-5108, an oral aurora a kinase inhibitor, administered both as monotherapy and in combination with docetaxel, in patients with advanced or refractory solid tumors
Manik Amin et al.
INVESTIGATIONAL NEW DRUGS (2016)
The potential role of the NEK6, AURKA, AURKB, and PAK1 genes in adenomatous colorectal polyps and colorectal adenocarcinoma
Elmas Kasap et al.
TUMOR BIOLOGY (2016)
Inhibiting the anaphase promoting complex/cyclosome induces a metaphase arrest and cell death in multiple myeloma cells
Susanne Lub et al.
Oncotarget (2016)
Open-Label, Multicenter, Phase 1 Study of Alisertib (MLN8237), an Aurora A Kinase Inhibitor, With Docetaxel in Patients With Solid Tumors
Julie N. Graff et al.
CANCER (2016)
Janus face-like effects of Aurora B inhibition: antitumoral mode of action versus induction of aneuploid progeny
Ralf Wiedemuth et al.
CARCINOGENESIS (2016)
A phase I trial of the aurora kinase inhibitor, ENMD-2076, in patients with relapsed or refractory acute myeloid leukemia or chronic myelomonocytic leukemia
Karen W. L. Yee et al.
INVESTIGATIONAL NEW DRUGS (2016)
Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial
Steven G. DuBois et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Aurora-A Kinase: A Potent Oncogene and Target for Cancer Therapy
Min Yan et al.
MEDICINAL RESEARCH REVIEWS (2016)
Plk1 Inhibitors in Cancer Therapy: From Laboratory to Clinics
Rosie Elizabeth Ann Gutteridge et al.
MOLECULAR CANCER THERAPEUTICS (2016)
A Phase I/II Study of the Investigational Drug Alisertib in Combination With Abiraterone and Prednisone for Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Abiraterone
Jianqing Lin et al.
ONCOLOGIST (2016)
Gastric Cancer Patients with High PLK1 Expression and DNA Aneuploidy Correlate with Poor Prognosis
Hajime Otsu et al.
ONCOLOGY (2016)
Inhibition of Bcl-xL sensitizes cells to mitotic blockers, but not mitotic drivers
Ailsa Bennett et al.
OPEN BIOLOGY (2016)
A phase II trial of AZD1152 in relapsed/refractory diffuse large B-cell lymphoma
Graham P. Collins et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents
Lorenzo Galluzzi et al.
CANCER CELL (2015)
Naturally Occurring Mutations in the MPS1 Gene Predispose Cells to Kinase Inhibitor Drug Resistance
Mark D. Gurden et al.
CANCER RESEARCH (2015)
Inhibition of polo like kinase 1 in sarcomas induces apoptosis that is dependent on Mcl-1 suppression
Jayasree S. Nair et al.
CELL CYCLE (2015)
A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy
Gautam Borthakur et al.
HAEMATOLOGICA (2015)
Phase 1 study of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in East Asian cancer patients: pharmacokinetics and recommended phase 2 dose
Karthik Venkatakrishnan et al.
INVESTIGATIONAL NEW DRUGS (2015)
First-in-human phase 1 study of filanesib (ARRY-520), a kinesin spindle protein inhibitor, in patients with advanced solid tumors
Patricia M. LoRusso et al.
INVESTIGATIONAL NEW DRUGS (2015)
Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study
Bohuslav Melichar et al.
LANCET ONCOLOGY (2015)
The addition of granulocyte-colony stimulating factor shifts the dose limiting toxicity and markedly increases the maximum tolerated dose and activity of the kinesin spindle protein inhibitor SB-743921 in patients with relapsed or refractory lymphoma: results of an international, multicenter phase I/II study
Owen A. O'Connor et al.
LEUKEMIA & LYMPHOMA (2015)
Therapeutic polo-like kinase 1 inhibition results in mitotic arrest and subsequent cell death of blasts in the bone marrow of AML patients and has similar effects in non-neoplastic cell lines
Claudia Muench et al.
LEUKEMIA RESEARCH (2015)
Targeting the Mitotic Catastrophe Signaling Pathway in Cancer
Margaret M. Mc Gee
MEDIATORS OF INFLAMMATION (2015)
Targeting Mitosis in Cancer: Emerging Strategies
Carmen Dominguez-Brauer et al.
MOLECULAR CELL (2015)
Spatiotemporal regulation of the anaphase-promoting complex in mitosis
Sushama Sivakumar et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2015)
Targeting Cdc20 as a novel cancer therapeutic strategy
Lixia Wang et al.
PHARMACOLOGY & THERAPEUTICS (2015)
Joined at the hip: kinetochores, microtubules, and spindle assembly checkpoint signaling
Carlos Sacristan et al.
TRENDS IN CELL BIOLOGY (2015)
Cellular responses to a prolonged delay in mitosis are determined by a DNA damage response controlled by Bcl-2 family proteins
Didier J. Colin et al.
OPEN BIOLOGY (2015)
A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy
Gautam Borthakur et al.
HAEMATOLOGICA (2015)
The Aurora B kinase in chromosome bi-orientation and spindle checkpoint signaling
Veronica Krenn et al.
FRONTIERS IN ONCOLOGY (2015)
Efficacy and safety of biweekly i.v. administrations of the Aurora kinase inhibitor danusertib hydrochloride in independent cohorts of patients with advanced or metastatic breast, ovarian, colorectal, pancreatic, small-cell and non-small-cell lung cancer: a multi-tumour, multi-institutional phase II study
P. Schoffski et al.
ANNALS OF ONCOLOGY (2015)
A Phase I Trial of AT9283 (a Selective Inhibitor of Aurora Kinases) in Children and Adolescents with Solid Tumors: A Cancer Research UK Study
Lucas Moreno et al.
CLINICAL CANCER RESEARCH (2015)
A Novel Time-Dependent CENP-E Inhibitor with Potent Antitumor Activity
Akihiro Ohashi et al.
PLOS ONE (2015)
Phase II study of treatment of advanced ovarian cancer with folate-receptor-targeted therapeutic (vintafolide) and companion SPECT-based imaging agent (99mTc-etarfolatide)
R. T. Morris et al.
ANNALS OF ONCOLOGY (2014)
Prometaphase arrest-dependent phosphorylation of Bcl-2 and Bim reduces the association of Bcl-2 with Bak or Bim, provoking Bak activation and mitochondrial apoptosis in nocodazole-treated Jurkat T cells
Cho Rong Han et al.
APOPTOSIS (2014)
A phase 1 and dose-finding study of LY2523355 (litronesib), an Eg5 inhibitor, in Japanese patients with advanced solid tumors
Hiroshi Wakui et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
Plk1 Inhibition Enhances the Efficacy of Androgen Signaling Blockade in Castration-Resistant Prostate Cancer
Zhe Zhang et al.
CANCER RESEARCH (2014)
A phase I schedule dependency study of the aurora kinase inhibitor MSC1992371A in combination with gemcitabine in patients with solid tumors
E. Raymond et al.
INVESTIGATIONAL NEW DRUGS (2014)
Investigational Aurora A kinase inhibitor alisertib (MLN8237) as an enteric-coated tablet formulation in non-hematologic malignancies: Phase 1 dose-escalation study
Gerald Falchook et al.
INVESTIGATIONAL NEW DRUGS (2014)
Translational Exposure-Efficacy Modeling to Optimize the Dose and Schedule of Taxanes Combined with the Investigational Aurora A Kinase Inhibitor MLN8237 (Alisertib)
Jessica J. Huck et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Synergistic blockade of mitotic exit by two chemical inhibitors of the APC/C
Katharine L. Sackton et al.
NATURE (2014)
Cellular senescence: from physiology to pathology
Daniel Munoz-Espin et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2014)
p53 deficiency enhances mitotic arrest and slippage induced by pharmacological inhibition of Aurora kinases
M. Marxer et al.
ONCOGENE (2014)
Alisertib Added to Rituximab and Vincristine Is Synthetic Lethal and Potentially Curative in Mice with Aggressive DLBCL Co-Overexpressing MYC and BCL2
Daruka Mahadevan et al.
PLOS ONE (2014)
A phase l study of three different dosing schedules of the oral aurora kinase inhibitor MSC1992371A in patients with solid tumors
M. Mita et al.
TARGETED ONCOLOGY (2014)
A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia
J. F. Seymour et al.
BLOOD CANCER JOURNAL (2014)
Selective Depletion of Regulatory T Cell Subsets by Docetaxel Treatment in Patients with Nonsmall Cell Lung Cancer
Jie-Yao Li et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2014)
Antimitotic drugs in cancer chemotherapy: Promises and pitfalls
Isabel Marzo et al.
BIOCHEMICAL PHARMACOLOGY (2013)
Aurora kinase A (AURKA) expression in colorectal cancer liver metastasis is associated with poor prognosis
J. A. C. M. Goos et al.
BRITISH JOURNAL OF CANCER (2013)
The combination of alisertib, an investigational Aurora kinase A inhibitor, and docetaxel promotes cell death and reduces tumor growth in preclinical cell models of upper gastrointestinal adenocarcinomas
Vikas Sehdev et al.
CANCER (2013)
Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia
Hagop M. Kantarjian et al.
CANCER (2013)
Targeting mitotic exit with hyperthermia or APC/C inhibition to increase paclitaxel efficacy
Serena Giovinazzi et al.
CELL CYCLE (2013)
Predictive Biomarkers of Sensitivity to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Breast Cancer Models
Jennifer R. Diamond et al.
CLINICAL CANCER RESEARCH (2013)
Tales of How Great Drugs Were Brought Down by a Flawed Rationale-Response
Edina Komlodi-Pasztor et al.
CLINICAL CANCER RESEARCH (2013)
Phase I Study Assessing the Safety and Tolerability of Barasertib (AZD1152) With Low-Dose Cytosine Arabinoside in Elderly Patients With AML
Hagop M. Kantarjian et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2013)
Mitosis and apoptosis: how is the balance set?
Caroline H. Topham et al.
CURRENT OPINION IN CELL BIOLOGY (2013)
Discontinued drugs in 2011: oncology drugs
Robert Williams
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2013)
Polyploidy road to therapy-induced cellular senescence and escape
Qin Wang et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Phase II study to assess the efficacy, safety and tolerability of the mitotic spindle kinesin inhibitor AZD4877 in patients with recurrent advanced urothelial cancer
Robert Jones et al.
INVESTIGATIONAL NEW DRUGS (2013)
A phase I, dose-escalation study of the Eg5-inhibitor EMD 534085 in patients with advanced solid tumors or lymphoma
A. Hollebecque et al.
INVESTIGATIONAL NEW DRUGS (2013)
PRECEDENT: A Randomized Phase II Trial Comparing Vintafolide (EC145) and Pegylated Liposomal Doxorubicin (PLD) in Combination Versus PLD Alone in Patients With Platinum-Resistant Ovarian Cancer
R. Wendel Naumann et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia
F. J. Giles et al.
LEUKEMIA (2013)
A phase I dose-escalation study of MSC1992371A, an oral inhibitor of aurora and other kinases, in advanced hematologic malignancies
Carlos Graux et al.
LEUKEMIA RESEARCH (2013)
Microtubule attachment and spindle assembly checkpoint signalling at the kinetochore
Emily A. Foley et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2013)
Critical role of anti-apoptotic Bcl-2 protein phosphorylation in mitotic death
J. M. Eichhorn et al.
CELL DEATH & DISEASE (2013)
Beyond taxanes: the next generation of microtubule-targeting agents
Javier Cortes et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
A phase 1 dose-escalation study of ARRY-520, a kinesin spindle protein inhibitor, in patients with advanced myeloid leukemias
Hanna Jean Khoury et al.
CANCER (2012)
First-time-in-human study of GSK923295, a novel antimitotic inhibitor of centromere-associated protein E (CENP-E), in patients with refractory cancer
Vincent Chung et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
CDK1, not ERK1/2 or ERK5, is required for mitotic phosphorylation of BIMEL
Rebecca Gilley et al.
CELLULAR SIGNALLING (2012)
Phase I/II multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in patients with refractory acute myeloid leukemia
H. M. Kantarjian et al.
INVESTIGATIONAL NEW DRUGS (2012)
Cyclin-dependent Kinase-1 (Cdk1)/Cyclin B1 Dictates Cell Fate after Mitotic Arrest via Phosphoregulation of Antiapoptotic Bcl-2 Proteins
Nandini Sakurikar et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Mitosis-targeted anti-cancer therapies: where they stand
K-S Chan et al.
CELL DEATH & DISEASE (2012)
Prognostic significance of Aurora-A expression in human bladder cancer
Yu Lei et al.
ACTA HISTOCHEMICA (2011)
Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors
E. Claire Dees et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors
Anne M. Traynor et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
Phase I Assessment of New Mechanism-Based Pharmacodynamic Biomarkers for MLN8054, a Small-Molecule Inhibitor of Aurora A Kinase
Arijit Chakravarty et al.
CANCER RESEARCH (2011)
Navitoclax (ABT-263) Accelerates Apoptosis during Drug-Induced Mitotic Arrest by Antagonizing Bcl-xL
Jue Shi et al.
CANCER RESEARCH (2011)
Cyclin B1 interacts with the BH3-only protein Bim and mediates its phosphorylation by Cdk1 during mitosis
Sean Mac Fhearraigh et al.
CELL CYCLE (2011)
Update on aurora kinase targeted therapeutics in oncology
Myke R. Green et al.
EXPERT OPINION ON DRUG DISCOVERY (2011)
Discontinued drugs in 2010: oncology drugs
Robert Williams
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2011)
Caspase activity is not required for the mitotic checkpoint or mitotic slippage in human cells
Kyunghee Lee et al.
MOLECULAR BIOLOGY OF THE CELL (2011)
Pharmacogenetic profiling of Aurora kinase B is associated with overall survival in metastatic colorectal cancer
A. Pohl et al.
PHARMACOGENOMICS JOURNAL (2011)
Sensing centromere tension: Aurora B and the regulation of kinetochore function
Michael A. Lampson et al.
TRENDS IN CELL BIOLOGY (2011)
Drug-Resistant Aurora A Mutants for Cellular Target Validation of the Small Molecule Kinase Inhibitors MLN8054 and MLN8237
Dominic A. Sloane et al.
ACS CHEMICAL BIOLOGY (2010)
Pharmacologic Inhibition of the Anaphase-Promoting Complex Induces A Spindle Checkpoint-Dependent Mitotic Arrest in the Absence of Spindle Damage
Xing Zeng et al.
CANCER CELL (2010)
A Novel Chemoimmunomodulating Property of Docetaxel: Suppression of Myeloid-Derived Suppressor Cells in Tumor Bearers
Krithika N. Kodumudi et al.
CLINICAL CANCER RESEARCH (2010)
Phosphorylation of Mcl-1 by CDK1-cyclin B1 initiates its Cdc20-dependent destruction during mitotic arrest
Margaret E. Harley et al.
EMBO JOURNAL (2010)
MLN8054, an Inhibitor of Aurora A Kinase, Induces Senescence in Human Tumor Cells Both In vitro and In vivo
Jessica J. Huck et al.
MOLECULAR CANCER RESEARCH (2010)
Phase I Study of the Selective Aurora A Kinase Inhibitor MLN8054 in Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, and Pharmacodynamics
Teresa Macarulla et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Stochastic Competition between Mechanistically Independent Slippage and Death Pathways Determines Cell Fate during Mitotic Arrest
Hsiao-Chun Huang et al.
PLOS ONE (2010)
Bcl-XL represents a druggable molecular vulnerability during aurora B inhibitor-mediated polyploidization
O. Jameel Shah et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Role of senescence and mitotic catastrophe in cancer therapy
Richa Singh et al.
CELL DIVISION (2010)
Evidence that Mitotic Exit Is a Better Cancer Therapeutic Target Than Spindle Assembly
Hsiao-Chun Huang et al.
CANCER CELL (2009)
AZD1152 Rapidly and Negatively Affects the Growth and Survival of Human Acute Myeloid Leukemia Cells In vitro and In vivo
Adedayo Oke et al.
CANCER RESEARCH (2009)
K858, a Novel Inhibitor of Mitotic Kinesin Eg5 and Antitumor Agent, Induces Cell Death in Cancer Cells
Ryuichiro Nakai et al.
CANCER RESEARCH (2009)
Chromosomal instability A composite phenotype that influences sensitivity to chemotherapy
Sarah E. McClelland et al.
CELL CYCLE (2009)
Discontinued drugs in 2008: oncology drugs
Robert Williams
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2009)
Inhibition of KSP by ARRY-520 induces cell cycle block and cell death via the mitochondrial pathway in AML cells
B. Z. Carter et al.
LEUKEMIA (2009)
Overexpression of Aurora B is associated with poor prognosis in epithelial ovarian cancer patients
Yi-Jen Chen et al.
VIRCHOWS ARCHIV (2009)
Cancer cells display intra- and interline variation profound following prolonged exposure to antimitotic drugs
Karen E. Gascoigne et al.
CANCER CELL (2008)
Molecular basis of drug resistance in Aurora kinases
Fiona Girdler et al.
CHEMISTRY & BIOLOGY (2008)
A phase I study of 17-allylamino-17-demethoxygeldanamycin combined with paclitaxel in patients with advanced solid malignancies
Suresh S. Ramalingam et al.
CLINICAL CANCER RESEARCH (2008)
Multisite phosphorylation regulates Bim stability and apoptotic activity
Anette Hubner et al.
MOLECULAR CELL (2008)
Overexpression of Eg5 causes genomic instability and tumor formation in mice
Andrew Castillo et al.
CANCER RESEARCH (2007)
AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo
Jing Yang et al.
BLOOD (2007)
Applying the discovery of the Philadelphia chromosome
Daniel W. Sherbenou et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Mitotic arrest and cell - Fate why and how mitotic inhibition of transcription drives mutually exclusive events
Mikhail V. Blagosklonny
CELL CYCLE (2007)
Mitotic checkpoint slippage in humans occurs via cyclin B destruction in the presence of an active checkpoint
Daniela A. Brito et al.
CURRENT BIOLOGY (2006)
Peripheral neuropathy induced by paclitaxel: Recent insights and future perspectives
CD Scripture et al.
CURRENT NEUROPHARMACOLOGY (2006)
Aurora B expression directly correlates with prostate cancer malignancy and influence prostate cell proliferation
P Chieffi et al.
PROSTATE (2006)
The microtubule stabilizing agent discodermolide is a potent inducer of accelerated cell senescence
LE Klein et al.
CELL CYCLE (2005)
Aurora B overexpression associates with the thyroid carcinoma undifferentiated phenotype and is required for thyroid carcinoma cell proliferation
R Sorrentino et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Strategies to overcome resistance to targeted protein kinase inhibitors
H Daub et al.
NATURE REVIEWS DRUG DISCOVERY (2004)
Identification of a novel Bcl-xL phosphorylation site regulating the sensitivity of taxol- or 2-methoxyestradiol-induced apoptosis
A Basu et al.
FEBS LETTERS (2003)
分享论文
